• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Adjuvant sorafenib for liver cancer: wrong stage, wrong dose.索拉非尼用于肝癌辅助治疗：分期错误，剂量错误。
Lancet Oncol. 2015 Oct;16(13):1279-81. doi: 10.1016/S1470-2045(15)00296-X.
2
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.索拉非尼辅助治疗肝细胞癌切除术后或消融后（STORM）：一项 3 期、随机、双盲、安慰剂对照试验。
Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.
3
Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma.索拉非尼对一名复发性肝细胞癌患者的完全缓解。
World J Gastroenterol. 2014 Oct 21;20(39):14505-9. doi: 10.3748/wjg.v20.i39.14505.
4
Sorafenib as an adjuvant therapy for resectable hepatocellular carcinoma: A single center experience.索拉非尼作为可切除肝细胞癌辅助治疗的单中心经验
J BUON. 2016 Sept-Oct;21(5):1189-1194.
5
Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.索拉非尼：晚期肝细胞癌及其他病症的金标准疗法。
Future Oncol. 2015;11(16):2263-6. doi: 10.2217/fon.15.161.
6
The role of sorafenib in hepatocellular carcinoma.索拉非尼在肝细胞癌中的作用。
Clin Adv Hematol Oncol. 2015 Apr;13(4):232-4.
7
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?从索拉非尼治疗晚期肝细胞癌7年经验中学习：索拉非尼是否优于索拉非尼？
Target Oncol. 2016 Aug;11(4):565-7. doi: 10.1007/s11523-016-0427-8.
8
Reply to M. Bouattour et al.对M. 布阿图尔等人的回复
J Clin Oncol. 2015 Aug 1;33(22):2486. doi: 10.1200/JCO.2015.61.6730. Epub 2015 Jun 1.
9
Treatment of intermediate-stage hepatocellular carcinoma.中期肝细胞癌的治疗
Clin Adv Hematol Oncol. 2015 Aug;13(8):501-3.
10
Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?晚期肝细胞癌中因可预见的安全原因而进行的阴性试验：我们对酪氨酸激酶抑制剂的药代动力学忽视多久了？
J Clin Oncol. 2015 Aug 1;33(22):2484-5. doi: 10.1200/JCO.2014.60.6954. Epub 2015 Jun 1.

引用本文的文献

1
Identification of two heterogeneous subtypes of hepatocellular carcinoma with distinct pathway activities and clinical outcomes based on gene set variation analysis.基于基因集变异分析鉴定出具有不同通路活性和临床结局的两种肝细胞癌异质性亚型。
Front Genet. 2024 Sep 10;15:1441189. doi: 10.3389/fgene.2024.1441189. eCollection 2024.
2
A comprehensive review of phytoconstituents in liver cancer prevention and treatment: targeting insights into molecular signaling pathways.肝癌防治中植物成分的综合述评：靶向分子信号通路的见解。
Med Oncol. 2024 May 4;41(6):134. doi: 10.1007/s12032-024-02333-5.
3
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.辅助信迪利单抗治疗切除术后高危肝细胞癌的随机、对照、Ⅱ期临床试验
Nat Med. 2024 Mar;30(3):708-715. doi: 10.1038/s41591-023-02786-7. Epub 2024 Jan 19.
4
The clonal expression genes associated with poor prognosis of liver cancer.与肝癌预后不良相关的克隆表达基因。
Front Genet. 2022 Aug 25;13:808273. doi: 10.3389/fgene.2022.808273. eCollection 2022.
5
Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma.肝细胞癌肿瘤微环境的异质性及不同免疫亚型的预后和免疫治疗反应分析
J Oncol. 2022 Mar 29;2022:1087399. doi: 10.1155/2022/1087399. eCollection 2022.
6
Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection.辅助性索拉非尼与根治性切除术后复发高危肝细胞癌患者预后的关联
Front Oncol. 2021 Sep 23;11:633033. doi: 10.3389/fonc.2021.633033. eCollection 2021.
7
Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects.肝细胞癌根治性治疗后的辅助治疗：现状与展望。
Genes Dis. 2020 Feb 29;7(3):359-369. doi: 10.1016/j.gendis.2020.02.002. eCollection 2020 Sep.
8
Targeting angiogenesis for liver cancer: Past, present, and future.肝癌的血管生成靶向治疗：过去、现在与未来。
Genes Dis. 2020 Apr 7;7(3):328-335. doi: 10.1016/j.gendis.2020.03.010. eCollection 2020 Sep.
9
Targeted therapy for hepatocellular carcinoma.肝细胞癌的靶向治疗。
Signal Transduct Target Ther. 2020 Aug 11;5(1):146. doi: 10.1038/s41392-020-00264-x.
10
Emerging agents and regimens for hepatocellular carcinoma.新兴的肝癌治疗药物和方案。
J Hematol Oncol. 2019 Oct 26;12(1):110. doi: 10.1186/s13045-019-0794-6.

本文引用的文献

1
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.索拉非尼辅助治疗肝细胞癌切除术后或消融后（STORM）：一项 3 期、随机、双盲、安慰剂对照试验。
Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.
2
Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster.贝伐珠单抗与微转移：重新审视临床前和临床过山车。
Pharmacol Ther. 2014 Feb;141(2):117-24. doi: 10.1016/j.pharmthera.2013.09.003. Epub 2013 Sep 27.
3
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.贝伐珠单抗辅助治疗三阴性乳腺癌（BEATRICE）：一项随机、3 期试验的主要结果。
Lancet Oncol. 2013 Sep;14(10):933-42. doi: 10.1016/S1470-2045(13)70335-8. Epub 2013 Aug 7.
4
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.贝伐珠单抗联合奥沙利铂为基础的化疗作为结肠癌的辅助治疗（AVANT）：一项 3 期随机对照临床试验。
Lancet Oncol. 2012 Dec;13(12):1225-33. doi: 10.1016/S1470-2045(12)70509-0. Epub 2012 Nov 16.
5
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.索拉非尼经导管动脉化疗栓塞术后治疗不可切除的肝细胞癌的日本和韩国患者的 III 期研究。
Eur J Cancer. 2011 Sep;47(14):2117-27. doi: 10.1016/j.ejca.2011.05.007.
6
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.索拉非尼在肝肾功能不全患者中的Ⅰ期及药代动力学研究：CALGB 60301
J Clin Oncol. 2009 Apr 10;27(11):1800-5. doi: 10.1200/JCO.2008.20.0931. Epub 2009 Mar 2.
7
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.索拉非尼在亚太地区晚期肝细胞癌患者中的疗效和安全性：一项III期随机、双盲、安慰剂对照试验。
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
8
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
9
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.新型Raf激酶和血管内皮生长因子受体抑制剂BAY 43 - 9006用于晚期难治性实体瘤患者的I期临床和药代动力学研究。
J Clin Oncol. 2005 Feb 10;23(5):965-72. doi: 10.1200/JCO.2005.06.124. Epub 2004 Dec 21.

Adjuvant sorafenib for liver cancer: wrong stage, wrong dose.

作者信息

Kelley Robin Kate

机构信息

University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143, USA.

出版信息

Lancet Oncol. 2015 Oct;16(13):1279-81. doi: 10.1016/S1470-2045(15)00296-X.

DOI:10.1016/S1470-2045(15)00296-X
PMID:26433814
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4811670/
Abstract
摘要